Providers adjust based on your progress, side effects, and evolving needs
It is a synthetic peptide derived from a partial sequence of human gastric juice protein BPC - specifically a 15-amino acid fragment (GlyGluProProProGlyLysProAlaAspAspAlaGlyLeuVal)
Phase 2 clinical data showed that starting at lower doses (1-2mg) partially mitigated gastrointestinal side effects compared to more aggressive starting doses
Each appointment is guided by clinical screening, personalized goals, and clean medical protocols
Beginning in 2009 Maedi decided to focus exclusively on special needs planning by founding M&L Special Needs Planning, LLC
Professor Sikirics research contributions include: Initial isolation and characterization of BPC-157 from human gastric secretions Extensive investigations of gastroprotective and tissue healing mechanisms Pioneering studies on musculoskeletal tissue repair including tendon and muscle healing Research on cardiovascular protective effects and vascular injury healing Over 400 published papers examining BPC-157s pleiotropic effects across organ systems His work has established BPC-157 as one of the most comprehensively studied components in peptide-based regenerative research, though human clinical validation remains absent